Reunion Common Shareholders to Receive Consideration of US$1.12 Per Share in Cash
Represents a 43.1% Premium to the 30-Day Volume Weighted Average Price
Reunion Presents Encouraging Phase 1 Final Analysis at American Society of Clinical Psychopharmacology Annual Meeting, Enabling Advancement into Phase 2 in 2H 2023
https://finance.yahoo.com/news/reunion-neuroscience-announces-us-13-113000384.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.